The field of cancer therapy is rapidly moving forward with the development of numerous prospective new agents designed to inhibit cellular factors involved in signal transduction, cell proliferation, and the onset of apoptosis. At the core of these biological processes are transcription factors that are the functional mediators of these effects. Transcription factors are the downstream targets of numerous signal transduction pathways that are central to the process of carcinogenesis. The Activator Protein-1 (AP-1) complex is one such factor that has a central role in multiple processes involved in tumorigenesis including proliferation, migration, invasion and metastasis. The focus of this review is, using AP-1 as a model, to discuss transcription factors as targets for cancer therapy. The feasibility of targeted disruption of AP-1 by various agents such as dominant-negative mutants, small molecule inhibitors, transcription factor decoys (TFD), chemotherapeutic drugs, chemoprevention agents, siRNA and natural products will be explored.
INTRODUCTION
Cancer is a multistep process emanating from an initial transforming event that triggers a succession of processes that alter the growth of normal cells. The initiating event frequently involves the activation of a signaling pathway(s). This can occur by multiple mechanisms, including increased ligand:receptor interactions, constitutive activation of signaling molecules resulting in the activation of signal transduction pathways that impact on transacting factors and their subsequent action on downstream target genes. Any one of these processes is a potential target for cancer therapy and a substantial amount of work has been done on inhibiting the function of proteins involved in activating signal transduction cascades (Fig. 1) . While much success has been achieved in the design of molecules that inhibit specific kinases and phosphatases, these molecules often impact multiple pathways required for normal cellular function. Since the large majority of factors affected in cancer are signaling molecules, their downstream effectors, the transcription factors, which are fewer in number, are promising targets for cancer therapy [1] . Oncogenic transcription factors are particularly good therapeutic targets since they often have increased expression and activity in a variety of cancers. Associated with this is the fact that they mediate signals coming from multiple different pathways, hence inhibiting their function will likely interfere with the function of numerous signaling molecules [1] . AP-1 is one such transcription factor whose expression and activity is altered in many cancers, including breast and ovarian, amongst others ( Table 1) . The fact that AP-1 has increased expression in many different cancers and increased activity in cancer cells suggests that it may be fundamental to the process of oncogenesis. Numer-*Address correspondence to this author at the Cell and Cancer Biology Branch, NCI, NIH, Bldg. 37, Rm 1130B, 37 Convent Drive, Bethesda, Maryland 20892; USA; Tel: 301-402-9586; E-mail: birrerm@mail.nih.gov ous studies have shown that inhibiting AP-1 function has a profound effect on the behavior of cancer cells and tumors, often interfering with the transformed phenotype [2] [3] [4] . Taken together, this suggests that AP-1 is a promising target for cancer therapy. Here we will discuss the role of AP-1 in the development of cancer and highlight studies that establish the feasibility of AP-1 as a target for cancer therapy.
A. AP-1 as a Mediator of Signal Transduction
The AP-1 transcription complex was originally described as a protein, which supported the basal activity of the metallothionein gene promoter and other phorbol ester inducible promoters [5] . Early studies have revealed the complexity and biologic importance of this transcriptional complex [4, [6] [7] [8] [9] . It is now well established that the complex is composed of the Jun and Fos family members along with a myriad of other proteins including members of the ATF gene family and other leucine zipper containing proteins [4, 10] . These proteins form dimers via their leucine zippers and bind to DNA in a sequence specific fashion via homologous basic regions within each protein partner [11, 12] . Detailed analyses by different groups have revealed that AP-1 components are the endpoint for many signaling cascades [13, 14] . Phosphorylation of AP-1 components by kinases such as the JNK and ERK MAP kinases are critical to the function of AP-1. Phosphorylation of these components is associated with functional activation of the AP-1 complex which can then regulate downstream target genes involved in a variety of biological functions [4] . AP-1 is critical in mediating cellular proliferation in response to mitogenic stimuli. This has been directly demonstrated by antibody microinjection studies and by studies of knockout mice [15, 16] . Further, it has now been well established that signals from multiple stress stimuli result in the activation of AP-1 [17] . Ovarian [9] Endometrial [78, 79] Hodgkins Lymphoma [80] Colorectal [81] Cervical [82] Lung and Bladder [83] Osteosarcoma [84] B. Role of AP-1 in Oncogenesis, Metastasis and Apoptosis
Since its early description, AP-1 has been implicated in biologic processes integral to cellular transformation including proliferation, invasion and motility. AP-1 can potentially impact early or late events in carcinogenesis [2] . Phorbol ester induced tumor promotion is clearly mediated in part by AP-1 while genes such as collagenase, stromelysin and metalloproteinases, known to be involved in tissue invasion and metastasis, are regulated by AP-1. In contrast to this, accumulating evidence suggests that AP-1 is involved in biologic processes, which may oppose cellular proliferation [2, 18, 19] . Results from our laboratory and others have demonstrated that increased expression of c-Jun/AP-1 can induce cellular differentiation [20] [21] [22] as assessed by the induction of differentiation markers and a slowing of cellular growth.
The biologic role of AP-1 in stress induced apoptosis remains to be defined, but in several systems AP-1 appears to be a critical element for induction of the apoptotic pathway [23] [24] [25] .
For AP-1 to translate such diverse signals at least 2 aspects of the complex are important: 1.) post-translational modification of its components, and 2.) overall protein composition of the complex. These aspects are what make this transcription complex a promising target as a therapeutic agent. The integration of diverse signals from the cell cytoplasm is mediated by protein kinase cascades, which result in the phosphorylation of AP-1 components [26, 27] . This is an important regulatory step in that it occurs rapidly in the absence of new protein synthesis and is required for many biologic processes. We have characterized the structure/function relationships of cJun and its potential role in the development of cancer [28] and have found that deregulated expression of cJun can induce morphologic changes and nonadherent cell growth in immortalized rat fibroblasts [29, 30] . The structural domains required for this activity have been well defined [31] [32] [33] . The role of phosphorylation remains complex, with some data supporting an increase in AP-1 activity and transformation associated with phosphorylation, while others suggest no relation or an inverse one [34] [35] [36] . Therapeutic agents targeting kinases and their upstream activators have received substantial investigation. One such example is a small molecule inhibitor of JNK kinase, which results in inhibition of JNK-induced AP-1 activation [37] . Numerous other examples of kinase inhibitors have also been reported [38, 39] and are not the focus of this review. We will instead discuss alternative methods used to inhibit the function of transcription factors as mediators of signaling pathways. Fig. (1) . Cascade of events resulting in different biologic endpoints. Each event in this cascade can be targeted by therapeutic agents. Transcription factors provide ideal targets for intervention using a range of both known and promising new agents.
C. Approaches Used to Inhibit AP-1 Activity in Cancer i. Dominant-Negative Mutants that Inhibit AP-1 Activity
A number of dominant-negative mutants have been developed that inhibit AP-1 activity. Utilizing our dominant negative mutants we have demonstrated a key role for cJun/AP-1 in various in vitro transformation systems [28, 33] and in vivo tumor formation [40] . These include mutations in all the functional domains of cJun; the transactivation domain, DNA-binding domain and Leucine zipper region. Of these, the most effective has been the transactivation domain mutant, Tam67, where amino acids 3-122 have been deleted rendering the protein unable to function as transcriptional activator [41] . The mechanism through which Tam67 inhibits AP-1 activity has been extensively studied and is thought to occur via one of two ways; (1) Tam67 can sequester endogenous Jun and Fos proteins resulting in low activity AP-1 complexes or (2) Tam67 homodimers may prevent AP-1 complexes from binding to endogenous promoters. The ability of Tam67 to interfere with AP-1 activity has been determined in various systems. It has been shown to inhibit TPA-induced AP-1 activity associated with invasion of mouse keratinocytes [42] and the development of skin tumors in mice can also effectively be inhibited by Tam67 [43, 44] . More recently, Tam67 has been shown to inhibit the transformation phenotype of ODC-and c-Ha-ras-transformed NIH-3T3 cells [40] . It must be noted, however, that in some contexts, Tam67 can have opposite effects. Disruption of AP-1 signaling by Tam67 in KB3 cells resulted in delayed apoptosis and increased survival relative to control cells, in response to vinblastine [25] .
In addition to Tam67, a dominant-negative mutant designated A-Fos has been shown to have an inhibitory effect on AP-1 activity [45] . This mutant was generated via the fusion of an amphipathic protein sequence to the N-terminal of the Fos leucine zipper and in this way interferes with the Jun:Fos interaction. A-Fos has been shown to have a significant inhibitory effect on the drug-resistance of KB85 and A2780/ CP70 cells [46] . These dominant-negative mutants have been invaluable tools in providing an understanding of the role of AP-1 in carcinogenesis. While important information has been obtained from these dominant-negative mutants, their use in therapies has limitations.
ii. Inhibition of AP-1 Activity with Chemotherapeutic and Chemopreventative Agents
While most chemotherapeutic agents have not specifically been developed to interfere with the function of transcription factors, it has become evident that these drugs affect numerous transcription factors, including AP-1. One example of this is taxol, a chemotherapeutic agent against breast and ovarian cancer, whose primary mode of action is disrupting microtubule formation. It has, however, also been shown to have additional cellular effects, including altering the regulation of genes involved in invasion and metastasis, such as MMP1 and MMP3, by inhibiting AP-1 binding to their promoters [47] . Although taxol inhibits AP-1 binding to the MMP promoters, it does not interfere with cell growth. It is likely, however, that in some cancers, inhibition of AP-1 binding and activity by taxol may impact the aggressiveness of the tumors. Taxol also appears to enhance AP-1 binding and activity in some cases. In ovarian and lung cancer cell lines, taxol-induced up-regulation of IL8 is mediated by AP-1 and NFKB [48, 49] . Also, exposure of RPMI-1788 B lymphoblasts to taxol results in apoptosis which is accompanied by an increase in AP-1 binding activity [50] . This increased binding is thought to be a result of increased JNK activity as an early response to taxol treatment.
We have shown that increased AP-1 expression and activity in breast cancer cells results in a more invasive and hormone resistant phenotype [51] . In addition, cJun/AP-1 overexpression in MCF7 breast cancer cells renders them insensitive to the growth inhibitory effects of taxol. AP-1 over-expression and activity thus appears to be associated with a more chemo-resistant phenotype. Similar findings have been reported in human breast cancer cells for chemoresistance to adriamycin [52] , where significantly highly levels of cJun and cFos were associated with the adriamycin resistant cells. Taken together, these studies suggest that the inhibition of transcription factors such as AP-1 may be beneficial to the treatment of chemo-resistant tumor cells.
Other chemotherapeutic agents such as the retinoids have also been shown to have an inhibitory effect on AP-1 activity [53] . These compounds together with taxol appear to have an inhibitory effect on breast cancer cells, possibly through the inhibition of AP-1 activity and other targets. Since increased AP-1 expression appears to associate with a more chemoresistant phenotype, inhibitors of AP-1 in combination with other chemotherapy regimens may be a useful alternative in the treatment of such cancers.
Chemopreventive agents have of late received increasing interest as valuable agents that can delay the onset of carcinogenesis [54] . Numerous chemopreventive agents including curcumin and resveratrol have been identified. The antitumor effects of resveratrol, as an example, have been proposed to occur via the inhibition of MAPKs and AP-1. Resveratrol inhibits TPA-induced binding of AP-1 to the COX-2 promoter and in this manner is thought to prevent TPAinduced tumor formation in mouse models [55] . Similarly, resveratrol has a significant inhibitory effect on AP-1 binding and activity in human melanoma cells [56] .
Studies on several natural chemopreventive compounds in colon cancer cells demonstrated that curcumin, resveratrol, phenethyl isothiocyanate and sulforaphane all inhibit AP-1 activity at high doses in both the absence and presence of TPA [57] . Since these agents are derived from natural compounds it has been suggested that they potentially have fewer side effects compared to conventional chemotherapies.
iii. Current Technologies as Potential Therapeutics Against Oncogenic Transcription Factors
While antisense RNA has proved useful for inhibiting gene expression, a limitation has been that antisense RNA oligonucleotides are prone to degradation by nucleases. Although the use of phosphorothioate oligonucleotides, alkyl modified nucleotides and morpholino oligonucleotides, render these antisense molecules less susceptible to degradation by RNAse H [58] , and increase the stability of the antisense RNA, these modifications have various side effects in model systems, including widespread cell death. For this reason few antisense RNA's are currently in clinical trials.
RNAi:
More recent technologies such as RNA interference have received much acclaim in the past few years as a more effective way of inhibiting the synthesis of specific proteins. RNAi oligonucleotides against both the cJun and cFos components of the AP-1 complex have been shown to have a significant inhibitory effect on the motility of human epidermoid carcinoma cells [59] . These oligonucleotides have a similar inhibitory effect on cell motility as that observed with the AP-1 dominant-negative mutant Tam67. siRNA against the Fra1 component of AP-1 has been shown to be effective at inhibiting invasion, angiogenesis and cell proliferation of MDA-MB231 breast cancer cells [60] . While not targeting the AP-1 complex specifically, RNAi against EGR in combination with small molecule inhibitors of the MEK1 pathway significantly inhibited AP-1 activation in ME180 cervical cancer cells [61] , suggesting that combination therapies of RNAi and small molecules will likely be more effective at inhibiting cancer progression that is mediated through AP-1 activated pathways.
Transcription factor decoys:
One of the newer technologies that may impact our understanding of transcription factors in disease progression and our ability to treat disease are transcription factor decoys (TFDs). This technology utilizes the fact that transcription factors bind specific consensus sequences within the promoters of the genes they regulate [62] . TFD's generally comprise a double stranded oligomer or single stranded oligonucleotide containing the DNA binding sequence for a particular transcription factor that mimics the double stranded structure. These oligonucleotides act as competitive binding sites for the specific transcription factor, preventing it from binding to its consensus binding sites within the promoters of genes, thus inhibiting its function. This technology has been applied effectively in cell culture and mouse models to inhibit the activity of NFK , E2F, Stat1, Sp1 and AP-1 [63] [64] [65] [66] [67] . The treatment of oral squamous cell carcinoma cells with AP-1 decoys interferes with the invasive ability of these cells [68] . This inhibition is thought to be due to the TFD's inhibition of AP-1's ability to activate the expression of uPA and uPAR, two genes associated with invasion and metastasis. While limited investigation on the effect of TFD's against AP-1 has been done on the growth of cancer cells, studies of AP-1-decoys in pulmonary cells have shown that specific AP-1 inhibition may be of therapeutic value in the control of asthma [69] . Although TFD's show promise as targeted therapies against specific transcription factors, there are certain limitations associated with the technology such as localization of TFD's to the cytoplasm thus lessening their desired effect of interfering with transcription factor interactions in the genome [70] . One possible approach to avoid this is to target these molecules to the nucleus using a nuclear localization signal.
Peptide nucleic acids:
One approach of targeting DNA sequences to the nucleus is with the use of peptides containing a nuclear localization signal. Recent studies have focused on combining the technologies of peptide nucleic acids (PNA's) with DNA chimeras as more effective tools to target transcription factor function [71, 72] . PNA-DNA chimeras have shown promise at inhibiting transcription factors such as NF B and Sp1 [73, 74] . Successful inhibition of these transcription factors can be achieved with PNA-DNA-PNA chimeras. Inhibition of repressor complexes has also been successfully achieved using this technology. A peptide that specifically binds BCL6 blocks co-repressor recruitment and disrupts BCL6-mediated repression, reactivating BCL6 target genes [75] . To date, no PNA-DNA chimeras have been described for AP-1 but the design of such molecules to interfere with AP-1 activity is certainly feasible using the AP-1 consensus sequence. This, however, presents one of the complexities of AP-1 DNA binding since it is not fully known whether binding typically only occurs at the adopted AP-1 consensus sequence. While the DNA sequence to which the AP-1 complex binds is frequently represented as the consensus TRE (TGACTCA), it is clear that this is not typical. Sequence differences within the AP-1 binding site and its flanking sequences are important in determining the binding affinities of different family members [76] . Defining the compositional "rules" for AP-1 transcriptional regulation and identifying "downstream" target genes will be critical towards understanding the role of AP-1 in cancer and designing therapies targeted against its function.
CONCLUSION
The multifactorial nature of tumorigenesis makes it difficult to develop effective therapeutic agents for cancer. While numerous agents exist for the treatment of cancer, many of them are not 100% effective. As the mechanisms of tumorigenesis become better defined, new therapeutic targets are being identified, and novel strategies are being developed to target these new molecular targets. Transcription factors are enticing targets for cancer therapy as they regulate a number of downstream target genes. Consequently, inhibiting their function will impact a broad range of cellular responses. AP-1, as an example, exerts effects on amongst others, invasion, motility and apoptosis, all processes associated with cancer. Thus, inhibiting AP-1 function would affect multiple cellular processes. A similar argument can be made for many other transcription factors. One of the critical aspects of utilizing transcription factors as therapeutic targets is to choose the appropriate ones to target, and also to be able to effectively inhibit the function of these transcription factors. This review has explored some of the new methodology that can be used to inhibit the function of transcription factors, and although more work needs to be done to refine these technologies, they hold much promise. It is clear that while numerous cancer therapies currently exist, they are not effective in all cases. Thus, there is a need for new and alternative molecular therapeutic targets and transcription factors are ideal candidates.
